1
|
Birch S, Nguyen L. Planning the future of oral health care workforce: Moving beyond demographic change. Community Dent Health 2024; 41:49-53. [PMID: 38078644 DOI: 10.1922/cdh_00145birch05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 03/28/2024]
Abstract
The adoption of Universal Health Coverage for oral health care will not be sufficient to ensure that health care resources are accessible in accordance with needs for care. Government intervention in planning and allocating resources will be required to replace traditional market forces if market failure is not to be replaced by government failure. In this paper we explore the limitations of current 'fixed in time' approaches to planning the oral health care workforce and present an enhanced dynamic model for workforce planning that responds directly to changes in population, evidence-based best practice and new models of care.
Collapse
Affiliation(s)
- S Birch
- Faculty of Business Economics and Law, The University of Queensland, Australia
| | - L Nguyen
- Faculty of Business Economics and Law, The University of Queensland, Australia
| |
Collapse
|
2
|
Gonzalez OA, Kirakodu S, Nguyen L, Ebersole JL. Macrophage-related gingival transcriptomic patterns and microbiome alterations in experimental periodontitis in nonhuman primates. J Periodontal Res 2023; 58:1148-1170. [PMID: 37610132 DOI: 10.1111/jre.13156] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 04/05/2023] [Accepted: 06/08/2023] [Indexed: 08/24/2023]
Abstract
OBJECTIVE This study examined the microbiome features specifically related to host macrophage polarization in health, initiation and progression of periodontitis, and in resolution samples using a nonhuman primate model of ligature-induced periodontitis. BACKGROUND The oral microbiome is a complex of bacterial phyla, genera, and species acquired early in life into the individual autochthonous oral ecology. The microbiome changes overtime in response to both intrinsic and extrinsic stressors, and transitions to a dysbiotic ecology at sites of periodontal lesions. METHODS Comparisons were made between the microbial and host features in young (≤7 years) and adult (≥12 years) cohorts of animals. Footprints of macrophage-related genes in the gingival tissues were evaluated using expression profiles including M0, M1, and M2 related genes. RESULTS Within the gingival tissues, similar macrophage-related gene patterns were observed with significant increases with disease initiation and continued elevation throughout disease in both age groups. Approximately, 70% of the taxa were similar in relative abundance between the two groups; however, the adults showed a large number of OTUs that were significantly altered compared with the younger animals. Developing a correlation map identified three major node levels of interactions that comprised approximately ⅓ of the Operational Taxonomic Units (OTUs) that dominated the microbiomes across the samples. Also noted was a much greater frequency of significant correlations of individual OTUs with the macrophage phenotype markers, compared with disease and resolution samples in both age groups, with a greater frequency in the younger group. Moreover, these correlations were assigned to differentially expressed genes representing M0, M1, and M2-related phenotypes. A cluster analyses across the macrophage-related transcriptome and the OTUs demonstrated multiple somewhat distinct bacterial consortia, incorporating both commensal and putative pathogens, linked to the gene responses that differed in health, disease, and resolution samples. Finally, there were minimal alterations in the OTUs in individual clusters with specific macrophage-related responses in the younger group, while in the adult samples substantial variations were noted with genes from all macrophage phenotypes. CONCLUSIONS The results confirmed important features that could reflect macrophage polarization in periodontal lesions, and provided some initial data supporting specific members of the oral microbiome feature prominently related to specific gene response patterns consistent with macrophages in the gingival tissues.
Collapse
Affiliation(s)
- O A Gonzalez
- Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, Kentucky, USA
- Division of Periodontology, College of Dentistry, University of Kentucky, Lexington, Kentucky, USA
| | - S Kirakodu
- Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, Kentucky, USA
| | - L Nguyen
- Department of Biomedical Sciences, School of Dental Medicine, University of Nevada Las Vegas, Las Vegas, Nevada, USA
| | - J L Ebersole
- Department of Biomedical Sciences, School of Dental Medicine, University of Nevada Las Vegas, Las Vegas, Nevada, USA
| |
Collapse
|
3
|
Schrank BR, Gallagher CM, Nguyen L, Morris VK, Holliday E, Newman A, Merriman K, Sudol VM, Chiao EY, Hawk E, Koong AC, Chang S. Sexual Orientation and Gender Identity (SOGI) Data Collection: Opportunities to Advance Best Clinical Practices for LGBTQ+ Patients in Radiation Oncology. Int J Radiat Oncol Biol Phys 2023; 117:e56. [PMID: 37785716 DOI: 10.1016/j.ijrobp.2023.06.770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) A long-standing barrier to progress against health disparities is the lack of data regarding cancer risks, prevalence, treatment, and outcomes for sexual and gender minority (SGM) patients. Sexual orientation and gender identity (SOGI) data are not routinely collected by individual oncologists, cancer centers, or most non-federal hospital systems. Alarmingly high proportions of SGM patients report discrimination in healthcare or avoid routine care due to perceived lack of acceptance in the healthcare system. For these and other reasons, healthcare institutions must adopt practices that promote an inclusive environment for all patients including those self-identified from SGM groups. One strategy to achieve this aim is through SOGI data collection. The purpose of this study was to pilot new procedures and training for SOGI data collection, the aims of this project were to standardize the collection of SOGI data for all new patients referred to the Division of Radiation Oncology; promote clinical staff awareness of SGM health disparities and strategies for fostering an inclusive hospital environment; and to provide SGM patients and caregivers educational resources and support systems tailored to their needs. MATERIALS/METHODS We designed a Quality Improvement program for collecting SOGI data, which was approved by our institution's QIAB. Patient access specialists (PAS) were trained to collect SOGI data from newly registered patients and enter the data into the electronic health record. Radiation Oncology staff completed surveys before and after SOGI training to estimate its impact on the provision of patient care. A Fisher's exact test was utilized to evaluate associations between training and provider-reported outcomes. RESULTS Within a 3-week period starting in January 2023, two 1-hour interactive training sessions were offered to twenty-five PAS. Three 1-hour training sessions were offered to twenty-seven Radiation Oncology clinical staff. (1) Confidence for incorporating SOGI classifiers around patients improved from before training (52%, 13/25) to after training (100%, 17/17) among medical providers surveyed (odds ratio (OR) 32, 95% confidence interval (CI) 0.70-1493, p = 0.005). Use of SOGI data in clinical decision making increased from before training (9/25, 36%) to after training (100%, 17/17) among medical providers (OR 60.79, 95% CI 3.271-1130, p<0.0001). (2) A clinical pathway for SGM patients was developed to facilitate referral to our institution's SGM patient support group and distribution of patient education materials focused on sexual health. CONCLUSION Establishing standardized SOGI data collection can facilitate the provision of tailored resources and care that meets the needs of patients and staff in a large comprehensive cancer center. Specialized training for staff developed through this initiative helps foster an inclusive and welcoming environment that promotes the integration, visibility, and advancement of SGM cancer care at our institution.
Collapse
Affiliation(s)
- B R Schrank
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C M Gallagher
- Department of Critical Care Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Nguyen
- Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - V K Morris
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Holliday
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Newman
- Department of Patient Safety, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - K Merriman
- Department of Tumor Registry, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - V M Sudol
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Y Chiao
- Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Hawk
- Department of Cancer Prevention & Pop Science, University of Texas MD Anderson Cancer Center, Houston, TX
| | - A C Koong
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Chang
- Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
4
|
Hall J, Dance MJ, Nguyen L, Repka MC, Chen X, Shen C. Hippocampal-Sparing Radiotherapy in Primary Sinonasal and Cutaneous Head and Neck Malignancies: A Feasibility Study. Int J Radiat Oncol Biol Phys 2023; 117:e586-e587. [PMID: 37785776 DOI: 10.1016/j.ijrobp.2023.06.1931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients with primary sinonasal and cutaneous head and neck (H&N) malignancies often receive meaningful hippocampal doses, but the hippocampus is not a classic avoidance structure in radiation planning of these primary sites. This series characterizes the feasibility and tradeoffs of hippocampal-sparing radiotherapy (HSRT) for patients with primary sinonasal and cutaneous H&N malignancies. MATERIALS/METHODS We retrospectively identified patients at a single institution treated definitively for primary sinonasal or cutaneous malignancies of the H&N. Each patient received (chemo)radiation and all received clinically-significant radiation dose to one or both hippocampi. We created new HSRT plans for each patient with intensity-modulated radiotherapy using original target and organ-at-risk (OAR) volumes. Hippocampi were contoured based on Radiation Therapy Oncology Group guidelines. Absolute and relative differences in radiation dose to the hippocampi, planning target volumes (PTV), and OARs were recorded. We used paired-samples t-tests to compare hippocampal and PTV dosimetric measures with and without HSRT. RESULTS Thirty-seven patients were included (22 sinonasal, 11 cutaneous H&N, and 4 parotid primary tumors). Median prescription dose was 6600cGy (range: 5000-7440cGy). The most common fractionation regimens were 200cGy/fraction daily (51%, 19/37 patients) and 120cGy/fraction twice daily (41%, 15/37 patients). There were significant decreases in hippocampal Dmax and D100% using HSRT without compromising PTV coverage (Table 1). HSRT resulted in a relative increase of mean lacrimal gland dose by an average of 3.8%, optic chiasm Dmax by 1.3%, and whole brain Dmax of 1.2%. However, other OAR doses were lower with HSRT, including parotid gland mean dose, lens Dmax, optic nerve Dmax, cochlea mean dose, brainstem Dmax, and whole brain mean dose. CONCLUSION HSRT is feasible and results in meaningful radiation dose reduction to the hippocampi without reducing PTV coverage or increasing dose to other OARs. The hippocampi should be regularly included as avoidance structures when treating primary sinonasal and cutaneous H&N tumors with radiation. We suggest target hippocampal constraints of Dmax < 1600cGy and D100% < 500cGy when feasible (without compromising PTV coverage). The clinical significance of HSRT in patients with primary H&N tumors should be investigated prospectively.
Collapse
Affiliation(s)
- J Hall
- Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC
| | - M J Dance
- Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC
| | - L Nguyen
- North Carolina School of Science and Mathematics, Durham, NC
| | - M C Repka
- Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC
| | - X Chen
- Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC
| | - C Shen
- Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC
| |
Collapse
|
5
|
Nguyen L, Joensson N, Kunze F, Zeiler T, Hadt J, Baumgarten K. Technikschulung als Basis für digitale Gesundheitskompetenz
– Anregungen zur Gestaltung von Angeboten für ältere
Menschen. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
6
|
Pezel T, Bernard A, Lavie-Badie Y, Dreyfus J, Bohbot Y, Fard D, Nguyen L, Biere L, Le Ven F, Canu M, Ribeyrolles S, Mion B, Fauvel C, Ternacle J, Cautela J, Le Tourneau T, Donal E, Lafitte S, Mansencal N, Coisne A. SIMULATOR study: Multicentre randomized study to assess the impact of SIMULation-bAsed Training on transoesophageal echocardiOgraphy leaRning for cardiology residents. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Jackulikova M, Tothova M, Byzovsky J, Olah M, Bielova M, Mlynarcik P, Vlcek R, Krcmery V, Nguyen L. Comparison of the Spectrum of Outpatient visits before and after Fire in the Moria Camp after Arrival of Covid-19 Positive Refugees. cswhi 2021. [DOI: 10.22359/cswhi_12_1_07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
8
|
Pepe P, Antevy P, Scheppke K, Marino M, Nichols E, Spencer E, Nguyen L, Redfleld C, Katz R, Babinec F, Rivkees S. 213 Age Differences among Persons With Positive COVID-19 Molecular Testing Later Testing Negative for Antibodies to SARS-CoV-2. Ann Emerg Med 2020. [PMCID: PMC7598378 DOI: 10.1016/j.annemergmed.2020.09.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Fakhfakh S, Pouliquen C, Campagna J, Loverde K, Treacy P, Maubon T, Rybikowski S, Cambon S, Nguyen L, Deguibert J, Laurent M, Aveno J, Bokor E, Demontis C, Forestier C, Bereni F, Galland J, Montoya C, Mejri I, Cea C, Faucher M, Mokart D, Pignot G, Walz J. Patient care pathway hypnosedation in endo urology: An innovative alternative to general anesthesia. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34225-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
10
|
Podboy A, Clarke J, Nguyen L, Mooney J, Dhillon G, Hwang J. Outcomes of Gastric Per-Oral Endoscopic Pyloromyotomy for Severe Gastroparesis in a Lung Transplant Patient Population. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Fedotov AV, Altinbas Z, Belomestnykh S, Ben-Zvi I, Blaskiewicz M, Brennan M, Bruno D, Brutus C, Costanzo M, Drees A, Fischer W, Fite J, Gaowei M, Gassner D, Gu X, Halinski J, Hamdi K, Hammons L, Harvey M, Hayes T, Hulsart R, Inacker P, Jamilkowski J, Jing Y, Kewisch J, Kankiya P, Kayran D, Lehn R, Liaw CJ, Litvinenko V, Liu C, Ma J, Mahler G, Mapes M, Marusic A, Mernick K, Mi C, Michnoff R, Miller T, Minty M, Narayan G, Nayak S, Nguyen L, Paniccia M, Pinayev I, Polizzo S, Ptitsyn V, Rao T, Robert-Demolaize G, Roser T, Sandberg J, Schoefer V, Schultheiss C, Seletskiy S, Severino F, Shrey T, Smart L, Smith K, Song H, Sukhanov A, Than R, Thieberger P, Trabocchi S, Tuozzolo J, Wanderer P, Wang E, Wang G, Weiss D, Xiao B, Xin T, Xu W, Zaltsman A, Zhao H, Zhao Z. Experimental Demonstration of Hadron Beam Cooling Using Radio-Frequency Accelerated Electron Bunches. Phys Rev Lett 2020; 124:084801. [PMID: 32167359 DOI: 10.1103/physrevlett.124.084801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 01/24/2020] [Accepted: 02/03/2020] [Indexed: 06/10/2023]
Abstract
Cooling of beams of gold ions using electron bunches accelerated with radio-frequency systems was recently experimentally demonstrated in the Relativistic Heavy Ion Collider at Brookhaven National Laboratory. Such an approach is new and opens the possibility of using this technique at higher energies than possible with electrostatic acceleration of electron beams. The challenges of this approach include generation of electron beams suitable for cooling, delivery of electron bunches of the required quality to the cooling sections without degradation of beam angular divergence and energy spread, achieving the required small angles between electron and ion trajectories in the cooling sections, precise velocity matching between the two beams, high-current operation of the electron accelerator, as well as several physics effects related to bunched-beam cooling. Here we report on the first demonstration of cooling hadron beams using this new approach.
Collapse
Affiliation(s)
- A V Fedotov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Altinbas
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Belomestnykh
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I Ben-Zvi
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Blaskiewicz
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Brennan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Bruno
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Brutus
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Costanzo
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Drees
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Fischer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Fite
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Gaowei
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Gassner
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - X Gu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Halinski
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Hamdi
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Hammons
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Harvey
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Hayes
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Hulsart
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Inacker
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Jamilkowski
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Y Jing
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Kewisch
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Kankiya
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Kayran
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Lehn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C J Liaw
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Litvinenko
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Liu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Ma
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Mahler
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Mapes
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Marusic
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Mernick
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Mi
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Michnoff
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Miller
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Minty
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Narayan
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Nayak
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Nguyen
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Paniccia
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - I Pinayev
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Polizzo
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Ptitsyn
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Rao
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | - T Roser
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Sandberg
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - V Schoefer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - C Schultheiss
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Seletskiy
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - F Severino
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Shrey
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - L Smart
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - K Smith
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H Song
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Sukhanov
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - R Than
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Thieberger
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S Trabocchi
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - J Tuozzolo
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - P Wanderer
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - E Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - G Wang
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D Weiss
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B Xiao
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - T Xin
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - W Xu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Zaltsman
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - H Zhao
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - Z Zhao
- Brookhaven National Laboratory, Upton, New York 11973, USA
| |
Collapse
|
12
|
Trenkle A, Syha M, Rheinheimer W, Callahan P, Nguyen L, Ludwig W, Lenthe W, Echlin MP, Pollock TM, Weygand D, De Graef M, Hoffmann MJ, Gumbsch P. Nondestructive evaluation of 3D microstructure evolution in strontium titanate. J Appl Crystallogr 2020. [DOI: 10.1107/s160057672000093x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Nondestructive X-ray diffraction contrast tomography imaging was used to characterize the microstructure evolution in a polycrystalline bulk strontium titanate specimen. Simultaneous acquisition of diffraction and absorption information allows for the reconstruction of shape and orientation of more than 800 grains in the specimen as well as porosity. Three-dimensional microstructure reconstructions of two coarsening states of the same specimen are presented alongside a detailed exploration of the crystallographic, topological and morphological characteristics of the evolving microstructure. The overall analysis of the 3D structure shows a clear signature of the grain boundary anisotropy, which can be correlated to surface energy anisotropy: the grain boundary plane distribution function shows an excess of 〈100〉-oriented interfaces with respect to a random structure. The results are discussed in the context of interface property anisotropy effects.
Collapse
|
13
|
Santos L, Lea V, Killingsworth M, Liyanage I, Nguyen L, Harvey S. 31. Finding human umbilical cords as the true origin of universal face emojis transcending persons of all ages, genders, culture, religion and ethnicity. Pathology 2020. [DOI: 10.1016/j.pathol.2020.01.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Kleivdal H, Kristiansen SI, Nilsen MV, Goksyr A, Briggs L, Holland P, McNabb P, Aasheim A, Aune T, Bates S, Bavington C, Caron D, Doucette G, Gago-Martinez A, Gallacer S, Grieve M, Haley S, Hess P, Hughes P, Léger C, Macaillou-Le Baut C, Myrland C, Neil T, Nguyen L, Ross K, Samdal I, Schaffner R, Smith E, Sosa S, Towers N, Tubaro A, Vaquero E, Wells M, Werner M, White P. Determination of Domoic Acid Toxins in Shellfish by Biosense ASP ELISAA Direct Competitive Enzyme-Linked Immunosorbent Assay: Collaborative Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/90.4.1011] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
A collaborative study was conducted on the Biosense amnesic shellfish poisoning (ASP) enzyme-linked immunosorbent assay (ELISA) for the determination of domoic acid (DA) toxins in shellfish in order to obtain interlaboratory validation data for the method. In addition, a method comparison study was performed to evaluate the ASP ELISA as an alternative to the current liquid chromatography (LC) reference method for DA determination. The study material comprised 16 shellfish samples, including blue mussels, Pacific oysters, and king scallops, spiked with contaminated mussel homogenates to contain 0.120 mg DA/kg shellfish flesh. The shellfish samples were extracted with 50% aqueous methanol, and the supernatants were directly analyzed. Sixteen participating laboratories in 10 countries reported data from the ASP ELISA, and 4 of these laboratories also reported data from instrumental LC analysis. The participating laboratories achieved interlaboratory precision estimates for the 8 Youden paired shellfish samples in the range of 1020% for RSDr (mean 14.8 4%), and 1329% for RSDR (mean 22.7 6%). The precision estimates for the ELISA data did not show a strong dependence on the DA concentration in the study samples, and the overall precision achieved was within the acceptable range of the Horwitz guideline with HorRat values ranging from 1.1 to 2.4 (mean HorRat 1.7 0.5). The analysis of shellfish samples spiked with certified reference material (CRM)-ASP-MUS-b gave recoveries in the range of 88122%, with an average recovery of 104 10%. The estimate on method accuracy was supported by a correlation slope of 1.015 (R2 = 0.992) for the determined versus the expected DA values. Furthermore, the correlation of the ASP ELISA results with those for the instrumental LC analyses of the same sample extracts gave a correlation slope of 1.29 (R2 = 0.984). This indicates some overestimation of DA levels in shellfish by the ELISA, but it is also a result of apparent low recoveries for the LC methods. This interlaboratory study demonstrates that the ASP ELISA is suitable for the routine determination and monitoring of DA toxins in shellfish, and that it offers a rapid and cost-effective methodology with high sample throughput.
Collapse
Affiliation(s)
- Hans Kleivdal
- Biosense Laboratories AS, HIB-Thormhlensgate 55, NO-5008 Bergen, Norway
| | | | - Mona V Nilsen
- Biosense Laboratories AS, HIB-Thormhlensgate 55, NO-5008 Bergen, Norway
| | - Anders Goksyr
- Biosense Laboratories AS, HIB-Thormhlensgate 55, NO-5008 Bergen, Norway
| | - Lyn Briggs
- AgResearch Ltd, Ruakura, East St, Hamilton, New Zealand
| | | | - Paul McNabb
- Cawthron Institute, 98 Halifax St East, Nelson, New Zealand
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Hsu CH, Nguyen L, Cheng AL, Nguyen T, Brendel K, Aslanis V, Benzaghou F. Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Butler M, Sotov V, Saibil S, Bonilla L, Boross-Harmer S, Fyrsta M, Gray D, Nelles M, Le M, Lemiashkova D, Liu D, Sacher A, Trang A, Vakili K, Van As B, Scheid E, Nguyen L, Takahashi S, Tanaka S, Hirano N. Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Telley L, Agirman G, Prados J, Amberg N, Fièvre S, Oberst P, Bartolini G, Vitali I, Cadilhac C, Hippenmeyer S, Nguyen L, Dayer A, Jabaudon D. Temporal patterning of apical progenitors and their daughter neurons in the developing neocortex. Science 2019; 364:eaav2522. [PMID: 31073041 DOI: 10.1126/science.aav2522] [Citation(s) in RCA: 165] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Accepted: 04/04/2019] [Indexed: 12/13/2022]
Abstract
During corticogenesis, distinct subtypes of neurons are sequentially born from ventricular zone progenitors. How these cells are molecularly temporally patterned is poorly understood. We used single-cell RNA sequencing at high temporal resolution to trace the lineage of the molecular identities of successive generations of apical progenitors (APs) and their daughter neurons in mouse embryos. We identified a core set of evolutionarily conserved, temporally patterned genes that drive APs from internally driven to more exteroceptive states. We found that the Polycomb repressor complex 2 (PRC2) epigenetically regulates AP temporal progression. Embryonic age-dependent AP molecular states are transmitted to their progeny as successive ground states, onto which essentially conserved early postmitotic differentiation programs are applied, and are complemented by later-occurring environment-dependent signals. Thus, epigenetically regulated temporal molecular birthmarks present in progenitors act in their postmitotic progeny to seed adult neuronal diversity.
Collapse
Affiliation(s)
- L Telley
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland.
| | - G Agirman
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
- GIGA-Stem Cells, University of Liège, C.H.U. Sart Tilman, Liège, Belgium
| | - J Prados
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
| | - N Amberg
- Institute of Science and Technology Austria, Klosterneuburg, Austria
| | - S Fièvre
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
| | - P Oberst
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
| | - G Bartolini
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
| | - I Vitali
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
| | - C Cadilhac
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
| | - S Hippenmeyer
- Institute of Science and Technology Austria, Klosterneuburg, Austria
| | - L Nguyen
- GIGA-Stem Cells, University of Liège, C.H.U. Sart Tilman, Liège, Belgium
| | - A Dayer
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland
- Department of Psychiatry, Geneva University Hospital, Geneva, Switzerland
| | - D Jabaudon
- Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland.
- Clinic of Neurology, Geneva University Hospital, Geneva, Switzerland
| |
Collapse
|
18
|
Coutance G, Lebreton G, Jacob N, Bréchot N, Demondion P, Bouglé A, Nguyen L, Varnous S, Combes A, Leprince P. A Direct Heart-Transplantation Strategy in Selected Patients on Extra-Corporeal Membrane Oxygenation Achieved Favorable Post-Transplant Outcomes. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.261] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
19
|
Barnouin OS, Daly MG, Palmer EE, Gaskell RW, Weirich JR, Johnson CL, Asad MMA, Roberts JH, Perry ME, Susorney HCM, Daly RT, Bierhaus EB, Seabrook JA, Espiritu RC, Nair AH, Nguyen L, Neumann GA, Ernst CM, Boynton WV, Nolan MC, Adam CD, Moreau MC, Risk B, D'Aubigny CD, Jawin ER, Walsh KJ, Michel P, Schwartz SR, Ballouz RL, Mazarico EM, Scheeres DJ, McMahon J, Bottke W, Sugita S, Hirata N, Hirata N, Watanabe S, Burke KN, DellaGuistina DN, Bennett CA, Lauretta DS. Shape of (101955) Bennu indicative of a rubble pile with internal stiffness. Nat Geosci 2019; 12:247-252. [PMID: 31080497 PMCID: PMC6505705 DOI: 10.1038/s41561-019-0330-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 02/15/2019] [Indexed: 05/18/2023]
Abstract
The shapes of asteroids reflect interplay between their interior properties and the processes responsible for their formation and evolution as they journey through the Solar System. Prior to the OSIRIS-REx (Origins, Spectral Interpretation, Resource Identification, and Security-Regolith Explorer) mission, Earth-based radar imaging gave an overview of (101955) Bennu's shape. Here, we construct a high-resolution shape model from OSIRIS-REx images. We find that Bennu's top-like shape, considerable macroporosity, and prominent surface boulders suggest that it is a rubble pile. High-standing, north-south ridges that extend from pole to pole, many long grooves, and surface mass wasting indicate some low levels of internal friction and/or cohesion. Our shape model indicates that, similar to other top-shaped asteroids, Bennu formed by reaccumulation and underwent past periods of fast spin leading to its current shape. Today, Bennu might follow a different evolutionary pathway, with interior stiffness permitting surface cracking and mass wasting.
Collapse
Affiliation(s)
- O S Barnouin
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - M G Daly
- The Centre for Research in Earth and Space Science, York University, Toronto, Ontario, Canada
| | - E E Palmer
- Planetary Science Institute, Tucson, AZ, USA
| | - R W Gaskell
- Planetary Science Institute, Tucson, AZ, USA
| | - J R Weirich
- Planetary Science Institute, Tucson, AZ, USA
| | - C L Johnson
- Planetary Science Institute, Tucson, AZ, USA
- Department of Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, Canada
| | - M M Al Asad
- Department of Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, Canada
| | - J H Roberts
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - M E Perry
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - H C M Susorney
- Department of Earth, Ocean and Atmospheric Sciences, University of British Columbia, Vancouver, Canada
| | - R T Daly
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - E B Bierhaus
- Lockheed Martin Space Systems Company, Denver, CO, USA
| | | | - R C Espiritu
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - A H Nair
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - L Nguyen
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - G A Neumann
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - C M Ernst
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - W V Boynton
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - M C Nolan
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - C D Adam
- KinetX Aerospace, Inc. Simi Valley, CA, USA
| | - M C Moreau
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - B Risk
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | | | - E R Jawin
- Smithsonian Institution National Museum of Natural History, Washington, DC, USA
| | - K J Walsh
- Southwest Research Institute, Boulder, CO, USA
| | - P Michel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, CNRS, Laboratoire Lagrange, Nice, France
| | - S R Schwartz
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - R-L Ballouz
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - E M Mazarico
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - D J Scheeres
- Department of Aerospace Engineering Sciences, University of Colorado, Boulder, CO, USA
| | - J McMahon
- Department of Aerospace Engineering Sciences, University of Colorado, Boulder, CO, USA
| | - W Bottke
- Southwest Research Institute, Boulder, CO, USA
| | - S Sugita
- University of Tokyo, Tokyo, Japan
| | - N Hirata
- Aizu University, Aizu-Wakamatsu, Japan
| | | | - S Watanabe
- Nagoya University, Nagoya, Japan
- Institute of Space and Astronautical Science, JAXA, Sagamihara, Japan
| | - K N Burke
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | | | - C A Bennett
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - D S Lauretta
- Lunar Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| |
Collapse
|
20
|
Hoffman J, Chakrabarti J, Wainberg ZA, Plotka A, Babu S, Milillo Naraine A, Kanamori D, Moroose R, Nguyen L, Wang D. Abstract P3-14-07: Evaluation of the effects of talazoparib on QT interval prolongation. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-14-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Talazoparib (TAL), an oral poly ADP-ribose polymerase inhibitor, is under investigation in multiple oncologic clinical trials and has been submitted to the US FDA for use in patients (pts) with germline BRCA-mutated, HER2-negative advanced breast cancer.
International Conference on Harmonisation guidance recommends all new drugs be evaluated for effects on cardiac repolarization in a well-controlled clinical study. For drugs for which such evaluation cannot be conducted in healthy volunteers (eg, most anticancer agents), collection of robust corrected QT (QTc) interval data from a dedicated QTc study (hybrid thorough QT/QTc study) in pts is required in the registration dossier. The effect of steady-state (ss) TAL (1 mg once daily) on cardiac repolarization in pts with advanced solid tumors was evaluated in an open-label phase 1 study (NCT03042910).
Methods: Continuous 12-lead electrocardiogram (ECG) recordings were collected at baseline (Day -1); time-matched pharmacokinetic (PK) samples and continuous ECG recordings were obtained on Days 1, 2, and 22 (when TAL concentrations achieved ss). On Day -1, pts had continuous 12-lead ECG recording starting at Time 0 (Day 1 dosing time) for 6 hrs. On Days 1 and 22, ECG recording started 45 min before TAL administration and continued for 6 hrs post dose and blood samples for PK were collected before dose and at 1, 2, 4, and 6 hrs post dose. On Day 2, a 30-min ECG recording and a PK sample were obtained before dose at Time 0.
Continuous ECG recordings were submitted to a central laboratory; triplicate 10-sec ECGs were extracted from a 5-min extraction window beginning 15 min before each PK collection time. ECG measurements were reported via blinded manual adjudication process and included PR interval, QT interval, RR interval, and QRS complex. The QT interval was corrected for effect of heart rate using Fridericia's correction (QTcF) and Bazett's correction (QTcB).
The estimate of change from time-matched baseline and its 2-sided 90% confidence interval (CI) was calculated for each nominal time point using PROC MEANS. Additionally, a prespecified PK/pharmacodynamic (PD) model was used to describe the relationship between plasma TAL concentrations ([TAL]) and QTc. The prespecified linear mixed-effects model included [TAL], time (categorical), and treatment with random pt effects on [TAL] and the intercept. If the upper bounds (UB) of 1-sided 95% CIs of time-matched ΔQTc for all ECG time points were <20 msec and the UB of 1-sided 95% CIs of the predicted ΔQTc at the mean ss maximum [TAL] was <20 msec, the effect of TAL on QTc was not of clinical relevance.
Results: 37 of 38 pts enrolled received TAL and were included in the ECG and PK/PD analyses. No pts had a postbaseline absolute maximum QTcF or QTcB ≥500 msec or ΔQTc ≥60 msec. The UB of the 1-sided 95% CI for the time-matched ΔQTcF and ΔQTcB were <12 msec at all nominal ECG time points. In the PK/PD analysis, the slopes (95% CI) of QTcF-[TAL] and QTcB-[TAL] relationships were -0.14 (-0.78 to 0.50) msec/ng/mL and -0.24 (-0.88 to 0.41) msec/ng/mL, respectively, indicating that TAL did not have a concentration-dependent effect on QTcF or QTcB.
Conclusion: TAL does not have a clinically relevant effect on QTc.
Funding: Medivation LLC, acquired by Pfizer.
Citation Format: Hoffman J, Chakrabarti J, Wainberg ZA, Plotka A, Babu S, Milillo Naraine A, Kanamori D, Moroose R, Nguyen L, Wang D. Evaluation of the effects of talazoparib on QT interval prolongation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-14-07.
Collapse
Affiliation(s)
- J Hoffman
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - J Chakrabarti
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - ZA Wainberg
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - A Plotka
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - S Babu
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - A Milillo Naraine
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - D Kanamori
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - R Moroose
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - L Nguyen
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| | - D Wang
- Pfizer, Inc., La Jolla, CA; Pfizer, Inc., Tadworth, United Kingdom; University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; Pfizer, Inc., Collegeville, PA; Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, IN; Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL; Comprehensive Blood and Cancer Center, Bakersfield, CA; Orlando Health, Inc., Orlando, FL; Pfizer, Inc., San Francisco, CA
| |
Collapse
|
21
|
Nguyen L, Bang S, Noh I. Tissue Regeneration of Human Mesenchymal Stem Cells on Porous Gelatin Micro-Carriers by Long-Term Dynamic In Vitro Culture. Tissue Eng Regen Med 2019; 16:19-28. [PMID: 30815347 PMCID: PMC6361098 DOI: 10.1007/s13770-018-00174-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Revised: 12/10/2018] [Accepted: 12/13/2018] [Indexed: 02/07/2023] Open
Abstract
Background Tissue engineering is a multidisciplinary field which attracted much attention in recent years. One of the most important issue in tissue engineering is how to obtain high cell numbers and tissue regeneration while maintaining appropriate cellular characteristics in vitro for restoring damaged or dysfunctional body tissues and organs. These demands can be achieved by the use of three dimensional (3D) dynamic cultures of cells combined with cell-adhesive micro-carriers. Method In this study, human mesenchymal stem cells (hMSCs) were cultured in a wave-bioreactor system for up to 100 days, after seeding on Cultisphere-S porous gelatin micro-carriers. Cell counting was performed at the time points of 7, 12, 17, 31 days and compared to those of hMSCs cultured under static condition. Higher growth and proliferation rates was achieved in wave-type dynamic culture, when cell culture continued to day 31. A scanning electron microscope (SEM) photographs, both live and dead and MTT assays were taken to confirm the survival and distribution of cells on porous gelatin micro-carrier surfaces. The results of histological stains such as hematoxylin and eosin, Masson's trichrome, Alcian blue and Alizarin red S also showed improved proliferation and tissue regeneration of hMSCs on porous gelatin micro-carriers. Conclusion The experimental results demonstrated the effect and importance of both micro-carriers and bioreactor in hMSC expansion on cell proliferation and migration as well as extracellular matrix formation on the superficial and pore surfaces of the porous gelatin micro-carriers, and then their inter-connections, leading to tissue regeneration.
Collapse
Affiliation(s)
- LeTuyen Nguyen
- Department of Chemical and Biomolecular Engineering, Seoul National University of Science and Technology, 232 Gongneung-ro, Nowon-gu, Seoul, 11811 Republic of Korea
| | - Sumi Bang
- Convergence Institute of Biomedical Engineering and Biomaterials, Seoul National University of Science and Technology, 232 Gongneung-ro, Nowon-gu, Seoul, 11811 Republic of Korea
| | - Insup Noh
- Department of Chemical and Biomolecular Engineering, Seoul National University of Science and Technology, 232 Gongneung-ro, Nowon-gu, Seoul, 11811 Republic of Korea
- Convergence Institute of Biomedical Engineering and Biomaterials, Seoul National University of Science and Technology, 232 Gongneung-ro, Nowon-gu, Seoul, 11811 Republic of Korea
| |
Collapse
|
22
|
Santos L, Gune S, Killingsworth M, Harvery M, Wuhrer R, Nguyen L, Wu X, Sabapathy S, Evangelista C, McNamara N, Yong J. 22. Finding live deer placenta stem cells in commercial food supplement capsules using cytology, histology, immunohistochemistry, flow cytometry, elemental analysis and electron microscopy. Pathology 2019. [DOI: 10.1016/j.pathol.2018.09.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Le Guillou F, Nguyen L, Stach B, Zanetti C, Antoun Z. Bilan initial de la prise en charge des exacerbations aiguës de BPCO (EABPCO) en pratique libérale. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Ebersole JL, Dawson DA, Emecen Huja P, Pandruvada S, Basu A, Nguyen L, Zhang Y, Gonzalez OA. Age and Periodontal Health - Immunological View. Curr Oral Health Rep 2018; 5:229-241. [PMID: 30555774 PMCID: PMC6291006 DOI: 10.1007/s40496-018-0202-2] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE OF THE REVIEW Aging clearly impacts a wide array of systems, in particular the breadth of the immune system leading to immunosenescence, altered immunoactivation, and coincident inflammaging processes. The net result of these changes leads to increased susceptibility to infections, increased neoplastic occurrences, and elevated frequency of autoimmune diseases with aging. However, as the bacteria in the oral microbiome that contribute to the chronic infection of periodontitis is acquired earlier in life, the characteristics of the innate and adaptive immune systems to regulate these members of the autochthonous microbiota across the lifespan remains ill defined. RECENT FINDINGS Clear data demonstrate that both cells and molecules of the innate and adaptive immune response are adversely impacted by aging, including in the oral cavity, yielding a reasonable tenet that the increased periodontitis noted in aging populations is reflective of the age-associated immune dysregulation. Additionally, this facet of host-microbe interactions and disease needs to accommodate the population variation in disease onset and progression, which may also reflect an accumulation of environmental stressors and/or decreased protective nutrients that could function at the gene level (ie. epigenetic) or translational level for production and secretion of immune system molecules. SUMMARY Finally, the majority of studies of aging and periodontitis have emphasized the increased prevalence/severity of disease with aging, all based upon chronological age. However, evolving areas of study focusing on "biological aging" to help account for population variation in disease expression, may suggest that chronic periodontitis represents a co-morbidity that contributes to "gerovulnerability" within the population.
Collapse
Affiliation(s)
- J L Ebersole
- Department of Biomedical Sciences, School of Dental Medicine, University of Nevada Las Vegas, Las Vegas, NV
| | - D A Dawson
- Division of Periodontology, College of Dentistry, University of Kentucky, Lexington, KY
| | - P Emecen Huja
- Department of Periodontics, JBE College of Dental Medicine, Medical University of South Carolina, Charleston, SC
| | - S Pandruvada
- Department of Oral Health Sciences, JBE College of Dental Medicine, Medical University of South Carolina, Charleston, SC
| | - A Basu
- Department of Kinesiology and Nutrition, School of Allied Health Sciences, University of Nevada Las Vegas, Las Vegas, NV
| | - L Nguyen
- Department of Biomedical Sciences, School of Dental Medicine, University of Nevada Las Vegas, Las Vegas, NV
| | - Y Zhang
- Southern Nevada Health District, Las Vegas, NV
| | - O A Gonzalez
- Department of Biomedical Sciences, School of Dental Medicine, University of Nevada Las Vegas, Las Vegas, NV
- Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
25
|
Nguyen L, Nie Q, Myers D, Gibson A, Kerssens C, Mudar R, Rogers W. SOCIAL ENGAGEMENT THROUGH VIDEO CHAT FOR OLDER INDIVIDUALS WITH AND WITHOUT COGNITIVE IMPAIRMENT. Innov Aging 2018. [DOI: 10.1093/geroni/igy031.3689] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- L Nguyen
- University of Illinois at Urbana-Champaign
| | - Q Nie
- University of Illinois at Urbana-Champaign
| | | | | | | | - R Mudar
- University of Illinois at Urbana-Champaign
| | - W Rogers
- University of Illinois at Urbana-Champaign
| |
Collapse
|
26
|
Butler M, Majeed H, Nelles M, Saibil S, Bonilla L, Boross-Harmer S, Sotov V, Elston S, Ross K, van As B, Le M, Fyrsta M, Lo C, Yam J, Nie J, Scheid L, Ohashi P, Nguyen L, Tanaka S, Hirano N. Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Helekar SA, Convento S, Nguyen L, John BS, Patel A, Yau JM, Voss HU. The strength and spread of the electric field induced by transcranial rotating permanent magnet stimulation in comparison with conventional transcranial magnetic stimulation. J Neurosci Methods 2018; 309:153-160. [PMID: 30194040 DOI: 10.1016/j.jneumeth.2018.09.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 08/16/2018] [Accepted: 09/02/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND Weak or low intensity transcranial stimulation of the brain, such as low field magnetic stimulation and electrical stimulation, can produce significant functional and therapeutic neuromodulatory effects. NEW METHOD We have recently developed a portable wearable multifocal brain stimulator called transcranial rotating permanent magnet stimulator (TRPMS) that uses rapidly spinning high field strength permanent magnets attached to a cap. It produces oscillatory stimuli of different frequencies and patterns. Here we compared the strengths and spatial profiles of the changing magnetic fields of a figure-of-eight transcranial magnetic stimulator (TMS) coil, a TRPMS prototype, and a scaled-up version of TRPMS. We measured field strengths and directions of voltages induced in a magnetic field sensor oriented along all three orthogonal axes. RESULTS AND COMPARISON WITH EXISTING METHODS The spatial spread of the TRPMS-induced electric field is more restricted, and its shape and strength vary less with the orientation of the inductance than TMS. The maximum voltage induced by the current prototype is ∼7% of the maximal TMS output at depths corresponding to the human cerebral cortex from the scalp surface. This field strength can be scaled up by a factor ∼8 with a larger diametrically magnetized magnet. These comparative data allow us to estimate that intracortical effects of TRPMS could be stronger than other low intensity stimulation methods. CONCLUSIONS TRPMS might enable greater uniformity, consistency and focality in stimulation of targeted cortical areas subject to significant anatomical variability. Multiple TRPMS microstimulators can also be combined to produce patterned multifocal spatiotemporal stimulation.
Collapse
Affiliation(s)
- S A Helekar
- Speech and Language Center, Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, TX, 77030, USA.
| | - S Convento
- Department of Neuroscience, Baylor College of Medicine, Houston, TX, 77030, USA
| | - L Nguyen
- Speech and Language Center, Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - B S John
- Speech and Language Center, Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - A Patel
- Speech and Language Center, Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, TX, 77030, USA
| | - J M Yau
- Department of Neuroscience, Baylor College of Medicine, Houston, TX, 77030, USA
| | - H U Voss
- Department of Radiology, Weill Cornell Medicine, New York, NY, 10021, USA
| |
Collapse
|
28
|
Coutance G, Leprince P, Demondion P, Jacob N, Nguyen L, Combes A, Amour J, Ouldamar S, Varnous S, Lebreton G. P4222Pre-heart transplantation ECMO support achieved favorable post-transplant outcomes in selected patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- G Coutance
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - P Leprince
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - P Demondion
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - N Jacob
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - L Nguyen
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - A Combes
- Hospital Pitie-Salpetriere, Intensive Care Unit, Paris, France
| | - J Amour
- Hospital Pitie-Salpetriere, Anesthesiology, Paris, France
| | - S Ouldamar
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - S Varnous
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| | - G Lebreton
- Hospital Pitie-Salpetriere, Cardiovascular and Thoracic surgery, Paris, France
| |
Collapse
|
29
|
Krzykawska-Serda M, Ware M, Lapin N, Agha M, Ho J, Law J, Newton J, Nguyen L, Curley S, Corr S. PO-438 Hyperthermia as neoadjuvant treatment for pancreatic tumours in murine models. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
30
|
Telli ML, Turner NC, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Hurvitz SA, Wardley AM, Fasching PA, Tudor C, Nguyen L, Hannah AL, Robson ME, Rugo HS. Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-14-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Talazoparib (TALA) is a dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor that traps PARP on DNA. Efficacy results of this phase 2 trial were previously presented (Turner et al, ASCO 2017, abstract 1007). This study included sparse pharmacokinetic (PK) sampling for patients through cycle 4 of therapy. Exploratory analyses included assessment of exposure versus parameters of efficacy and safety.
Methods: ABRAZO (NCT02034916) was a parallel-cohort, open-label phase 2 study of TALA (1 mg/d) following (i) platinum-based therapy (cohort 1) or (ii) ≥3 platinum-free cytotoxic-based regimens (cohort 2) in patients with locally advanced or metastatic breast cancer and germline BRCA1/2 mutation. Sparse PK sampling was performed on day 1 of cycles 1-4, consisting of a predose sample collected ≤60 minutes prior to dosing and 2 postdose samples collected ≥30 minutes after dosing (time of food ingestion prior to the dose was collected). The collection times of the 2 postdose samples were separated by ≥2 hours. Efficacy parameters included radiographic progression-free survival (rPFS) by central review and objective response rate (ORR). Safety parameters included incidence of overall adverse events (AEs) and grade ≥3 AEs. Individual AUCs (area under concentration-time curves) for exposure-response analyses were predicted by population PK analyses.
Results: Patients were divided into AUC tertiles: low (median, 109.0 ng*hr/mL; n=27), intermediate (median, 170.8 ng*hr/mL; n=27), and high (median, 219.2 ng*hr/mL; n=27). Median rPFS was 5.3 months (95% confidence interval [CI], 3.1, 8.3) in the lowest AUC tertile, 5.6 months (95% CI, 3.7, 8.4) in the intermediate AUC tertile, and 5.3 months (95% CI, 3.9, 5.6) in the highest AUC tertile. The ORR was 22.2% (95% CI, 8.6, 42.3) in the lowest AUC tertile, 25.9% (95% CI, 11.1, 46.3) in the intermediate AUC tertile, and 37.0% (95% CI, 19.4, 57.6) in the highest AUC tertile. AEs of any grade were reported in 11 patients (40.7%) in the lowest AUC tertile, 21 patients (77.8%) in the intermediate AUC tertile, and 22 patients (81.5%) in the highest AUC tertile. Grade ≥3 AEs were reported in 8 patients (29.6%) in the lowest AUC tertile and in 18 patients (66.7%) in the intermediate and highest AUC tertiles. The most common AEs in all 3 exposure tertiles were anemia, thrombocytopenia, and neutropenia.
Conclusions: Median rPFS did not change with increasing systemic exposure. There may be a trend to higher ORR in patients with highest systemic exposure. A larger percentage of patients experienced AEs with elevated systemic exposure. Increased response rates with greater exposure does not translate to improved rPFS. These results should be interpreted with caution due to the low patient numbers in each cohort.
Citation Format: Telli ML, Turner NC, Mailliez A, Ettl J, Grischke E-M, Mina LA, Balmaña J, Hurvitz SA, Wardley AM, Fasching PA, Tudor C, Nguyen L, Hannah AL, Robson ME, Rugo HS. ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-14-03.
Collapse
Affiliation(s)
- ML Telli
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - NC Turner
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - A Mailliez
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - J Ettl
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - E-M Grischke
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - LA Mina
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - J Balmaña
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - SA Hurvitz
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - AM Wardley
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - PA Fasching
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - C Tudor
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - L Nguyen
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - AL Hannah
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - ME Robson
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - HS Rugo
- Stanford University School of Medicine, Stanford, CA; Royal Marsden Hospital, The Institute of Cancer Research, London, United Kingdom; Centre Oscar Lambret, Lille, France; Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Universitats-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; Banner Health, Phoenix, AZ; Hospital Vall d'Hebron, Barcelona, Spain; University of California Los Angeles Health, Santa Monica, CA; The NIHR Cancer Research UK Christie Clinical Research Facility, Manchester, United Kingdom; University of Erlangen, Erlangen, Germany; Medivation, Inc. (Medivation was Acquired by Pfizer Inc., in September 2016), San Francisco, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| |
Collapse
|
31
|
Nguyen L, Squara P, Amour J, Cholley B. Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: A phase II trial. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.084] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Baudinaud P, Brusset A, Estagniasie P, Nicot F, Squara P, Nguyen L. Heart failure with preserved ejection fraction as risk factor of mortality after cardiothoracic surgery. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Raherison C, Ouaalaya E, Bernady A, Casteigt J, Dupis J, Nocent-Ejnaini C, Sabatini M, Falque L, Le Guillou F, Nguyen L, Ozier A, Molimard M. Quels sont les déterminants de la dyspnée chez les patients BPCO de la cohorte PALOMB ? Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Waldner DM, Giraldo Sierra NC, Bonfield S, Nguyen L, Dimopoulos IS, Sauvé Y, Stell WK, Bech-Hansen NT. Cone dystrophy and ectopic synaptogenesis in a Cacna1f loss of function model of congenital stationary night blindness (CSNB2A). Channels (Austin) 2018; 12:17-33. [PMID: 29179637 PMCID: PMC5972796 DOI: 10.1080/19336950.2017.1401688] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 10/22/2017] [Accepted: 10/31/2017] [Indexed: 01/05/2023] Open
Abstract
Congenital stationary night blindness 2A (CSNB2A) is an X-linked retinal disorder, characterized by phenotypically variable signs and symptoms of impaired vision. CSNB2A is due to mutations in CACNA1F, which codes for the pore-forming α1F subunit of a L-type voltage-gated calcium channel, Cav1.4. Mouse models of CSNB2A, used for characterizing the effects of various Cacna1f mutations, have revealed greater severity of defects than in human CSNB2A. Specifically, Cacna1f-knockout mice show an apparent lack of visual function, gradual retinal degeneration, and disruption of photoreceptor synaptic terminals. Several reports have also noted cone-specific disruptions, including axonal abnormalities, dystrophy, and cell death. We have explored further the involvement of cones in our 'G305X' mouse model of CSNB2A, which has a premature truncation, loss-of-function mutation in Cacna1f. We show that the expression of genes for several phototransduction-related cone markers is down-regulated, while that of several cellular stress- and damage-related markers is up-regulated; and that cone photoreceptor structure and photopic visual function - measured by immunohistochemistry, optokinetic response and electroretinography - deteriorate progressively with age. We also find that dystrophic cone axons establish synapse-like contacts with rod bipolar cell dendrites, which they normally do not contact in wild-type retinas - ectopically, among rod cell bodies in the outer nuclear layer. These data support a role for Cav1.4 in cone synaptic development, cell viability, and synaptic transmission of cone-dependent visual signals. Although our novel finding of cone-to-rod-bipolar cell contacts in this mouse model of a retinal channelopathy may challenge current views of the role of Cav1.4 in photopic vision, it also suggests a potential new target for restorative therapy.
Collapse
Affiliation(s)
- D. M. Waldner
- Department of Neuroscience, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - N. C. Giraldo Sierra
- Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - S. Bonfield
- Department of Neuroscience, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - L. Nguyen
- Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - I. S. Dimopoulos
- Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Y. Sauvé
- Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, Canada
- Department of Physiology, University of Alberta, Edmonton, Alberta, Canada
| | - W. K. Stell
- Department of Cell Biology and Anatomy and Department of Surgery, Hotchkiss Brain Institute, and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - N. T. Bech-Hansen
- Department of Medical Genetics, and Department of Surgery, Alberta Children's Hospital Research Institute, and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
35
|
Nguyen L, Tosun AB, Fine JL, Taylor DL, Chennubhotla SC. ARCHITECTURAL PATTERNS FOR DIFFERENTIAL DIAGNOSIS OF PROLIFERATIVE BREAST LESIONS FROM HISTOPATHOLOGICAL IMAGES. Proc IEEE Int Symp Biomed Imaging 2017; 2017:152-155. [PMID: 28890755 DOI: 10.1109/isbi.2017.7950490] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The differential diagnosis of proliferative breast lesions, benign usual ductal hyperplasia (UDH) versus malignant ductal carcinoma in situ (DCIS) is challenging. This involves a pathologist examining histopathologic sections of a biopsy using a light microscope, evaluating tissue structures for their architecture or size, and assessing individual cell nuclei for their morphology. Imposing diagnostic boundaries on features that otherwise exist on a continuum going from benign to atypia to malignant is a challenge. Current computational pathology methods have focused primarily on nuclear atypia in drawing these boundaries. In this paper, we improve on these approaches by encoding for both cellular morphology and spatial architectural patterns. Using a publicly available breast lesion database consisting of UDH and three different grades of DCIS, we improve the classification accuracy by 10% over the state-of-the-art method for discriminating UDH and DCIS. For the four way classification of UDH and the three grades of DCIS, our method improves the results by 6% in accuracy, 8% in micro-AUC, and 19% in macro-AUC.
Collapse
Affiliation(s)
- L Nguyen
- Department of Computational and Systems Biology, University of Pittsburgh.,Drug Discovery Institute, University of Pittsburgh
| | - A B Tosun
- Department of Computational and Systems Biology, University of Pittsburgh
| | - J L Fine
- Magee Womens Hospital of UPMC and Department of Pathology, University of Pittsburgh
| | - D L Taylor
- Department of Computational and Systems Biology, University of Pittsburgh.,Drug Discovery Institute, University of Pittsburgh
| | - S C Chennubhotla
- Department of Computational and Systems Biology, University of Pittsburgh.,Drug Discovery Institute, University of Pittsburgh
| |
Collapse
|
36
|
Nguyen L, Whitehall J, Edwards M. Accuracy of clinical coding for febrile seizures and implications for activity-based funding. Intern Med J 2017. [DOI: 10.1111/imj.11_13462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- L Nguyen
- Western Sydney University; Campbelltown New South Wales Australia
| | - J Whitehall
- Western Sydney University; Campbelltown New South Wales Australia
| | - M Edwards
- Western Sydney University; Campbelltown New South Wales Australia
| |
Collapse
|
37
|
Parkman HP, Hallinan EK, Hasler WL, Farrugia G, Koch KL, Calles J, Snape WJ, Abell TL, Sarosiek I, McCallum RW, Nguyen L, Pasricha PJ, Clarke J, Miriel L, Lee L, Tonascia J, Hamilton F. Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil 2016; 28:1902-1914. [PMID: 27350152 PMCID: PMC5125878 DOI: 10.1111/nmo.12893] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Accepted: 05/30/2016] [Indexed: 12/13/2022]
Abstract
BACKGROUND Nausea and vomiting are classic symptoms of gastroparesis. It remains unclear if characteristics of nausea and vomiting are similar in different etiologies of gastroparesis. The aims of this article were as follows: to describe characteristics of nausea and vomiting in patients with gastroparesis and to determine if there are differences in nausea and vomiting in diabetic (DG) and idiopathic gastroparesis (IG). METHODS Gastroparetic patients enrolling in the NIDDK Gastroparesis Registry underwent assessment with history and questionnaires assessing symptoms, quality of life, and a questionnaire characterizing nausea and vomiting. KEY RESULTS Of 159 gastroparesis patients (107 IG, 52 DG), 96% experienced nausea, whereas 65% experienced vomiting. Nausea was predominant symptom in 28% and vomiting was predominant in 4%. Nausea was severe or very severe in 41%. PAGI-SYM nausea/vomiting subscore was greater with increased vomiting severity, but not nausea severity in DG than IG. Nausea was related to meals in 71%; lasting most of the day in 41%. Increasing nausea severity was related to decreased quality of life. Nausea often preceded vomiting in 82% of patients and vomiting often relieved nausea in 30%. Vomiting was more common in DG (81%) compared to IG (57%; p = 0.004). Diabetic patients more often had vomiting in the morning before eating, during the night, and when not eating. CONCLUSIONS & INFERENCES Nausea is present in essentially all patients with gastroparesis irrespective of cause and associated with decreased quality of life. In contrast, vomiting was more prevalent, more severe, and occurred more often in DG than IG. Thus, characteristics of vomiting differ in IG vs DG.
Collapse
Affiliation(s)
| | | | | | | | - K. L. Koch
- Wake Forest University; Winston-Salem NC USA
| | - J. Calles
- Wake Forest University; Winston-Salem NC USA
| | - W. J. Snape
- California Pacific Medical Center; San Francisco CA USA
| | | | | | | | - L. Nguyen
- Stanford University; Palo Alto CA USA
| | | | - J. Clarke
- Johns Hopkins University; Baltimore MD USA
| | - L. Miriel
- Johns Hopkins University; Baltimore MD USA
| | - L. Lee
- Johns Hopkins University; Baltimore MD USA
| | | | - F. Hamilton
- National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda MD USA
| | | |
Collapse
|
38
|
Affiliation(s)
- S Farag
- Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
| | - L Nguyen
- Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
| | - T Kalir
- Pathology, Ichan School of Medicine at Mount Sinai, New York, New York
| | - D Fishman
- Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|
39
|
Nguyen L, Pluim C, Schiehser D, Turk E, Lessig S, Song D, Litvan I, Filoteo J. C-61Predictors of Freezing of Gait in Parkinson's Disease: The Influence of Mood and Cognition. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Pluim C, Nguyen L, Schiehser D, Turk E, Lessig S, Song D, Litvan I, Filoteo J. C-58The Impact of Dopamine Agonists on Sensitivity to Punishment and Sensitivity to Reward in Individuals with Parkinson's Disease. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
McDuffie JE, Chen Y, Ma JY, Lee S, Lynch KM, Hamlin DM, Nguyen L, Rizzolio M, Sonee M, Snook S. Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine. Toxicol Res (Camb) 2016; 5:1202-1215. [PMID: 30090426 DOI: 10.1039/c5tx00497g] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 05/19/2016] [Indexed: 11/21/2022] Open
Abstract
This 10-day (D) study was conducted to evaluate changes in traditional and newer kidney safety biomarker expression levels in dogs. Animals received cisplatin (CDDP, 0.75 mg per kg per day) or 0.9% Saline (vehicle) for 5 days. Serum/urine samples were collected at various time points. Cage-side observations included emesis (D1-2/D4-D5/D7-9), absence of stool (D5-9/D11), soft stool (D4-7/D12), excessive salivation (D1/D3/D5-6), decreased food consumption (D5-8), decreased activity (D7-8) and/or dehydration (D7). Animals were necropsied when serum creatinine (sCr) levels measured at ≥1.9 mg dL-1, indicating significant loss of renal function; or at the end of the study (D11). When compared to controls, increases in BUN/sCr were detected on D3, D5 and/or D8. Increases in urinary total protein (Ur TP) were noted on D6. The moribund dog that was euthanized early on D7 showed insignificant increases in urinary osteopontin (Ur OPN), urinary neutrophil gelatinase-associated lipocalin (Ur NGAL), urinary clusterin (Ur CLU), sCr, serum cystatin C (sCYS C) and urinary cystatin C (Ur CYS C) on D5 when compared to controls. Insignificant increases in urinary albumin (Ur ALB) were observed from an animal that was euthanized on D7 and 1 : 2 surviving animals on D8 relative to baseline. From three dogs that were euthanized on D9, increases in Ur CLU, and/or sCYS C were noted on D8 relative to baseline. The two surviving dogs showed elevated Ur CLU and 1 : 2 surviving dogs showed elevated Ur CYS C. Decreased urinary kidney injury molecule 1 (Ur KIM-1) on D3/D5 was evident (versus baseline and controls). CDDP-induced cortico-medullary lesions were characterized as minimal to mild tubule degeneration/necrosis, dilatation, regeneration, cell alteration, intratubular casts, interstitial inflammation and vacuolization. Increased Ur OPN and Ur CLU correlated with enhanced OPN and CLU immunopositive staining in damaged cortical epithelium in the proximal tubules. Enhanced KIM-1 staining in damaged cortico-medullary tubular epithelium appeared in the absence of rises in Ur KIM-1. This study showed changes in kidney safety protein biomarkers associated with CDDP nephrotoxicity in dogs and possibly in humans.
Collapse
Affiliation(s)
- J E McDuffie
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - Y Chen
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - J Y Ma
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - S Lee
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - K M Lynch
- Department of Safety Assessment , GlaxoSmithKline , King of Prussia , PA , USA
| | - D M Hamlin
- Investigative Toxicology , Eli Lilly & Co. , Indianapolis , IN , USA
| | - L Nguyen
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - M Rizzolio
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| | - M Sonee
- Discovery Sciences , Janssen Research & Development , L.L.C. , Spring House , PA , USA
| | - S Snook
- Discovery Sciences , Janssen Research & Development , L.L.C. , San Diego , CA , USA .
| |
Collapse
|
42
|
Chaudhry A, Nguyen L, Constantin E. Obesity and Ethnicity: Obstructive Sleep Apnea Risk Factors Poorly Represented in Sleep Apnea Screening Questionnaires. Paediatr Child Health 2016. [DOI: 10.1093/pch/21.supp5.e74a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND: The gold standard for the diagnosis of pediatric obstructive sleep apnea (OSA) is polysomnography, a resource-intensive tool that is not easily accessible. It has been shown thatquestionnaires cannot accurately diagnose OSA in children. However,questionnaires are often used as screening tools for OSA to help clinicians prioritize objective sleep testing in sleep laboratories. Although many tools exist to screen for OSA, there is significant variability in the elements they take into consideration.
OBJECTIVES: To identify all questionnaires that screen for OSA in children and to review and contrast items within these questionnaires.
DESIGN/METHODS: We conducted a review of the literature to identify all questionnaires for pediatric OSA. We searched PubMed (keywords: sleep disordered breathing, OSA, sleep apnea and risk factor) and the health and psychosocial instruments (HaPi) database. We also checked reference lists of all included articles. Questionnaires were included in the analysis if their primary goal was to identify or screen for pediatric OSA in children 0-18 years old. We described the questionnaires qualitatively by identifying all items within each questionnaire, including demographics, risk factors, signs, symptoms, and outcomes.
RESULTS: The search yielded 476 articles. After reviewing titles and abstracts, 130 articles were included of which 60 articles were deemed relevant for final analysis based on predetermined inclusion criteria. Forty-two questionnaires were identified. Thirty-two questionnaires containing 48 different items were included in the analysis. Items most commonly included in questionnaires were: snoring (78%), observed apnea (78%) and daytime sleepiness (75%). Other clinically relevant items, such as ethnicity (6%), and body mass index (31%), were not consistently included. Thirty-one questionnaires used quantitative scores to identify OSA. One questionnaire derived a formula to identify OSA, in which certain items (risk factors) were assigned relative weights. Moreover, most questionnaires sought to predict the diagnosis of OSA without emphasis on OSA severity.
CONCLUSION: There are currently several questionnaires that aim to screen children for OSA. However, these questionnaires rarely include known OSA risk factors such as ethnicityand obesityand are not able to screen for OSA severity.
Collapse
|
43
|
Johnson L, Bunn W, Nguyen L, Rice J, Raj M, Cunningham M. Clinical comparison of robotic, laparoscopic, and open hysterectomy procedures for endometrial cancer patients. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Bradley C, Nguyen L, Garcia-Larrea L. ID 226 – Inter-individual differences in laser-evoked potentials and operculo-insular morphology. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
|
46
|
Raherison C, Berteaud E, Bernady A, Blanchard E, Casteigt J, Nocent-Eijnani C, Falque L, Jungmann H, Le Guillou F, Moinard J, Nguyen L, Ozier A, Prud’homme A, Roy C, Sabatini M, Pellet F. Comment sont pris en charge les patients BPCO ? Données de la cohorte Palomb. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
47
|
Hwang IH, Choi YW, Kim KB, Park GJ, Lee JJ, Nguyen L, Noh I, Kim C. A highly selective and sensitive fluorescent turn-on Al3+ chemosensor in aqueous media and living cells: experimental and theoretical studies. NEW J CHEM 2016. [DOI: 10.1039/c5nj02334c] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A highly selective and sensitive fluorescent chemosensor exhibited enhanced fluorescence in the presence of Al3+ and in living cells.
Collapse
Affiliation(s)
- In Hong Hwang
- Department of Fine Chemistry and Department of Interdisciplinary Bio IT Materials
- Seoul National University of Science and Technology
- Korea
| | - Ye Won Choi
- Department of Fine Chemistry and Department of Interdisciplinary Bio IT Materials
- Seoul National University of Science and Technology
- Korea
| | - Kyung Beom Kim
- Department of Fine Chemistry and Department of Interdisciplinary Bio IT Materials
- Seoul National University of Science and Technology
- Korea
| | - Gyeong Jin Park
- Department of Fine Chemistry and Department of Interdisciplinary Bio IT Materials
- Seoul National University of Science and Technology
- Korea
| | - Jae Jun Lee
- Department of Fine Chemistry and Department of Interdisciplinary Bio IT Materials
- Seoul National University of Science and Technology
- Korea
| | - LeTuyen Nguyen
- Department of Chemical and Biomolecular Engineering
- and Convergence Program of Biomedical Engineering and Biomaterials
- Seoul National University of Science & Technology
- Republic of Korea
| | - Insup Noh
- Department of Chemical and Biomolecular Engineering
- and Convergence Program of Biomedical Engineering and Biomaterials
- Seoul National University of Science & Technology
- Republic of Korea
| | - Cheal Kim
- Department of Fine Chemistry and Department of Interdisciplinary Bio IT Materials
- Seoul National University of Science and Technology
- Korea
| |
Collapse
|
48
|
Hernandez-Mejia M, Prendiville B, Fong C, Burke M, Nguyen L, Schiehser D, Turk E, Delis D, Filoteo J. A-27The Impact of Reduced Retrieval Demands on Verbal Memory in Parkinson's Disease Patients at Various Levels of Global Cognitive Functioning. Arch Clin Neuropsychol 2015. [DOI: 10.1093/arclin/acv047.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
49
|
Longhi S, Mercolini F, Carloni L, Nguyen L, Fanolla A, Radetti G. Prematurity and low birth weight lead to altered bone geometry, strength, and quality in children. J Endocrinol Invest 2015; 38:563-8. [PMID: 25540042 DOI: 10.1007/s40618-014-0230-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 12/14/2014] [Indexed: 12/30/2022]
Abstract
PURPOSE Prematurity and low birth weight are associated with a decrease in bone mass. Aim of the study was to investigate bone geometry, strength, and quality in children born at term small for gestational age (term SGA), premature appropriate for gestational age (prem AGA), and premature SGA (prem SGA). METHODS 91 patients (46 f, 45 m), mean age 11.28 years, height SDS 0.03 ± 0.21, and BMI SDS -0.31 ± 0.19. 20 were term SGA, 22 prem SGA, and 49 prem AGA. Bone geometry was assessed on the 2nd metacarpal bone, by evaluating the outer and inner diameter, the cortical area, medullary area, metacarpal index, cross-sectional area, and bone strength. Bone quality was evaluated by ultrasound and expressed as amplitude-dependent speed of sound and bone transmission time (BTT). RESULTS Term SGA, prem SGA, and prem AGA had values of bone geometry, strength, and quality significantly lower than our reference range (p < 0.05). Findings in the three groups were similar, apart from BTT, which was significantly reduced in prem SGA (p < 0.05). Fat percentage was the main determinant of BTT. CONCLUSIONS Children born either prematurely or SGA seem to have smaller and weaker bones. Those born both premature and SGA were the most affected.
Collapse
Affiliation(s)
- S Longhi
- Department of Pediatrics, Regional Hospital, Via L. Boehler 5, 39100, Bolzano, Italy
| | - F Mercolini
- Department of Pediatrics, Regional Hospital, Via L. Boehler 5, 39100, Bolzano, Italy
| | - L Carloni
- Department of Pediatrics, Regional Hospital, Via L. Boehler 5, 39100, Bolzano, Italy
| | - L Nguyen
- Clinical Biochemistry Laboratory, Regional Hospital, Bolzano, Italy
| | - A Fanolla
- Department of Biostatistics, Regional Hospital, Bolzano, Italy
| | - G Radetti
- Department of Pediatrics, Regional Hospital, Via L. Boehler 5, 39100, Bolzano, Italy.
| |
Collapse
|
50
|
Dorzin E, Nguyen L, Anderson E, Bunn W, Cunningham M. Effect of body mass index on conversion rate and complications among patients undergoing robotic surgery for endometrial cancer. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|